Device Spine/Spine Surgery

Creo Mis Stabilization System

Payments companies reported to CMS as associated with Creo Mis Stabilization System. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$2.6Massociated payments (2023-2025)
207clinicians with associated payments
1company reporting

By year

2023 $1.3M
2024 $1.2M

Payments reported as associated with Creo Mis Stabilization System, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Orthopaedic Surgery of The Spine $1.7M
Neurological Surgery $785K
Orthopaedic Surgery $56K
Orthopaedic Trauma $2,016
Dentist $419
Orthodontics and Dentofacial Orthopedics $270

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Creo Mis Stabilization System

These are the largest totals companies reported as associated with Creo Mis Stabilization System. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Donald Johnson Mt Pleasant, SC Orthopaedic Surgery of The Spine $714,054.69
Chad Prusmack Lone Tree, CO Neurological Surgery $358,106.58
Choll Kim San Diego, CA Orthopaedic Surgery of The Spine $357,270.09
Steven Poletti Mt Pleasant, SC Orthopaedic Surgery of The Spine $346,091.39
Stefan Mindea Stanford, CA Neurological Surgery $179,093.08
Todd Doerr Scottsdale, AZ Orthopaedic Surgery of The Spine $178,797.07
Paul Park Memphis, TN Neurological Surgery $177,377.13
Deepak Reddy South Bend, IN Orthopaedic Surgery of The Spine $21,750.95
Mohammed Khan Oradell, NJ Neurological Surgery $21,250.00
Wyatt Ramey Cypress, TX Neurological Surgery $14,085.62

Prescribed Creo Mis Stabilization System?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.